A friend who has lived with HIV for years switched to a newer once-a-day pill a while back. His viral load is still undetectable, but his belt has moved two notches and the extra weight sits around his middle. Someone in an online group tells him tesamorelin, sold as Egrifta, is the fix. His real question is narrower: does it work for people taking today’s integrase-inhibitor regimens, which are tied to weight gain?
The only dedicated look is small. In a 2024 analysis of 38 people with HIV on integrase-based treatment, drawn from a year-long placebo-controlled trial, tesamorelin cut deep belly fat and liver fat, and blood sugar did not worsen more than with placebo. It did not test total body weight as a goal, and it involved a prescription drug used under medical care.
Why integrase inhibitors come up in weight conversations
Integrase strand transfer inhibitors, such as dolutegravir and bictegravir, are now the backbone of most first-line HIV treatment because they suppress the virus well and are easy to take. Weight gain has been a recurring finding alongside them.
A pooled analysis of eight randomized trials, covering more than 5,000 people starting HIV treatment between 2003 and 2015, found weight gain was greater in more recent trials and with newer regimens. Integrase inhibitors were linked to more gain than older drug classes, with dolutegravir and bictegravir ahead of elvitegravir. Tenofovir alafenamide was also linked to more gain than older tenofovir forms. Lower starting CD4 counts, higher viral loads, female sex and Black race were tied to more gain too, and the authors stressed that some gain reflects a return to health.
The ADVANCE trial in South Africa, which randomized 1,053 people, showed the pattern in practice. After 48 weeks, average weight rose 6.4 kg with dolutegravir plus tenofovir alafenamide, 3.2 kg with dolutegravir plus the older tenofovir, and 1.7 kg with the efavirenz-based standard regimen. Both lean and fat mass increased, and the gain was largest among women.
What the integrase subgroup of the tesamorelin trial found
Tesamorelin is a lab-made version of growth hormone-releasing hormone, a peptide that signals the pituitary gland. Its approval in people with HIV rests on trials that ran before integrase inhibitors were widespread, which left open whether it would behave the same way on current treatment.
Researchers at Massachusetts General Hospital went back to their randomized, double-blind trial of 61 people with HIV and fatty liver disease, registered as NCT02196831, and looked at the 38 who were on integrase-based regimens at the start. Fifteen on tesamorelin and 16 on placebo completed the 12 months.
Measured by MRI, visceral fat, the deep fat packed around the organs, fell by a median of 25 square centimeters on tesamorelin and rose by 14 on placebo. Liver fat dropped by a median of 4.2 percentage points compared with 0.5 on placebo. The ratio of trunk fat to arm and leg fat also improved. Adverse events, including high blood sugar, were reported at similar rates in both groups.
The limits matter. This was a subgroup of an existing trial rather than a study designed for integrase users, and the numbers per arm were small. One author reported consulting for Theratechnologies, which markets Egrifta. The results speak to belly and liver fat on scans, not to scale weight or long-term heart outcomes.
What this means for the friend, and what it does not
The useful takeaway is about matching the problem to the tool. Tesamorelin targets deep abdominal fat in people with HIV; it is not a general weight-loss drug, and a heavier scale reading on an integrase regimen is not the same thing as the fat pattern tesamorelin was tested on. A waist measurement and a talk with the HIV clinician are a better starting point than a forum tip.
He should not change or stop his HIV regimen on his own because of weight; that decision belongs with the care team, who can weigh viral control, drug interactions and other options. The NIH HIVinfo fact sheet on lipodystrophy describes how fat changes in HIV are assessed and managed.
The online pitch is also worth separating from the evidence. The trials used prescription Egrifta under medical supervision. Tesamorelin listed by online sellers as a research chemical is a different matter: those products are labeled for laboratory research, not for human use, and none was tested in these studies.
Sources
- Russo SC et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 2024 (PubMed)
- ClinicalTrials.gov NCT02196831: parent placebo-controlled tesamorelin trial in HIV and fatty liver disease
- Sax PE et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis, 2020 (PubMed)
- Venter WDF et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV (ADVANCE). N Engl J Med, 2019 (PubMed)
- NIH HIVinfo: HIV and lipodystrophy
Related reading
- Tesamorelin Lowered Liver Fat in a Small HIV Trial, With Open Questions
- Egrifta Targets HIV Lipodystrophy Fat, Not General Weight Loss
- Stopping Egrifta: Deep Belly Fat Built Back Up in the Trials
By The Everyday Brief. AI-assisted drafting with automated source and editorial checks. Sources fetched 2026-10-26 PT. Not medical advice.